Cixutumumab

N/A

Report date: 2024/04/18 14:29:47

Base Information

Drug NameCixutumumab
Drug Alias Namecixutumumabum西舒妥木单抗西妥木单抗LY-3012217IMC-A12 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsUveal melanomaMedullary thyroid cancer (MTC)Esophageal adenocarcinoma +[72] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesStanford UniversityEli Lilly And CompanyThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsEsophageal adenocarcinomaStomach NeoplasmsEsophageal Neoplasms +[5] 
Inactive IndicationsUveal melanomaMedullary thyroid cancer (MTC)Metastatic breast cancer +[67] 

Other Information

ATC CodeN/A
Related LinksN/A